majority of INCY investors are not influenced by 2nd Q. earning
Look into past events ,don't put too much weight on undeserving scare talks ....this company has large pipeline under development so expenses will weigh on finance but accomplishments are well accepted by pros.
accomplishments yes, so far there is only ONE, Incyte has stated 6 Q's ago that they would get the 60million from NVS, Incyte stated they would SUBMIT for sNDA for PV in June, and HAVE approval before year end, these are big statements to make, the street can be very unforgiving........when management tries to manage wall street expects you get what happened just recently, share price from 70 to 40, and then 58.50 pre ASCO and then too 44 before presentation
How come you always focus on incy without looking at macro trends? Almost every biotech had their high of the year on feb23. The recent consolidation/pullback had zero to do with not delivering something that the street expected, and everything to do with a biotech bubble popping.